Cabaletta Bio Inc. (CABA)
Cabaletta Bio Statistics
Share Statistics
Cabaletta Bio has 48.88M shares outstanding. The number of shares has increased by 1.24% in one year.
| Shares Outstanding | 48.88M |
| Shares Change (YoY) | 1.24% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 78.6% |
| Shares Floating | 44.47M |
| Failed to Deliver (FTD) Shares | 2.58K |
| FTD / Avg. Volume | 0.21% |
Short Selling Information
The latest short interest is 3.71M, so 7.58% of the outstanding shares have been sold short.
| Short Interest | 3.71M |
| Short % of Shares Out | 7.58% |
| Short % of Float | 8.96% |
| Short Ratio (days to cover) | 4.26 |
Valuation Ratios
The PE ratio is -0.96 and the forward PE ratio is -0.93. Cabaletta Bio's PEG ratio is -0.02.
| PE Ratio | -0.96 |
| Forward PE | -0.93 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 0.73 |
| P/FCF Ratio | -1.23 |
| PEG Ratio | -0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cabaletta Bio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.15, with a Debt / Equity ratio of 0.1.
| Current Ratio | 6.15 |
| Quick Ratio | 6.15 |
| Debt / Equity | 0.1 |
| Debt / EBITDA | -0.12 |
| Debt / FCF | -0.17 |
| Interest Coverage | 167.3 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-719.65K |
| Employee Count | 161 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -92.58% in the last 52 weeks. The beta is 2.58, so Cabaletta Bio's price volatility has been higher than the market average.
| Beta | 2.58 |
| 52-Week Price Change | -92.58% |
| 50-Day Moving Average | 2.03 |
| 200-Day Moving Average | 4.04 |
| Relative Strength Index (RSI) | 28.42 |
| Average Volume (20 Days) | 1.2M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -125.14M |
| Net Income | -115.86M |
| EBITDA | -125.14M |
| EBIT | -116.61M |
| Earnings Per Share (EPS) | -2.37 |
Balance Sheet
The company has 163.96M in cash and 15.6M in debt, giving a net cash position of 148.36M.
| Cash & Cash Equivalents | 163.96M |
| Total Debt | 15.6M |
| Net Cash | 148.36M |
| Retained Earnings | -349.1M |
| Total Assets | 204.41M |
| Working Capital | 162.63M |
Cash Flow
In the last 12 months, operating cash flow was -88.22M and capital expenditures -2.21M, giving a free cash flow of -90.43M.
| Operating Cash Flow | -88.22M |
| Capital Expenditures | -2.21M |
| Free Cash Flow | -90.43M |
| FCF Per Share | -1.85 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CABA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CABA is $23, which is 1785.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $23 |
| Price Target Difference | 1785.2% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | -1.81 |
| Piotroski F-Score | 2 |